Colloplus

Quick links to important sections

Colloplus

Selected form

Method of action: Emollients And Protectives

Treatment option: Warts

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colloplus

What is Colloplus? (Overview)

Property Description
Active Ingredients Salicylic acid and Lactic acid
Form Topical Solution
Pharmacological Class Keratolytic Agents
Common Action Chemical Exfoliation and Tissue Softening
Origin Combination Chemical Drug

What Type of Medicine is Colloplus?

Colloplus is a high-strength topical combination medicine classified as a keratolytic agent, designed for precise external application to the skin. This classification means its primary function is to break down and soften keratin, the protein structure that forms thick or hardened skin. As a combination chemical drug, it blends the two well-established active ingredients, Salicylic acid and Lactic acid, to maximize its efficacy.

The combination of these two acids is recognized for its exfoliating properties, differentiating it from single-ingredient treatments. This formulation, which often uses a collodion-like base, allows the solution to dry and form a protective, water-resistant film over the application site, which is a distinctive feature ensuring prolonged contact with the target tissue.

What is the Composition and Form?

Colloplus is supplied as a potent topical solution, meaning it is a liquid formulation intended for targeted delivery onto a small area of the skin. It contains the active acids suspended in a solvent base which helps the product adhere strongly and dry quickly over the treated site. This physical form is a key factor, as the liquid vehicle allows the active ingredients to achieve sustained contact and penetrate the dense, affected tissue. This form is designed for localized, intensive treatment.

What is the General Purpose of a Keratolytic?

The general purpose of Colloplus is to initiate the softening and peeling away of hardened, excess skin tissue through a process of chemical exfoliation. The combined action of Salicylic and Lactic acids helps dissolve the substances holding the rigid skin cells together. This mechanism helps the abnormal skin layers naturally slough off over time, supporting the replacement of rigid tissue with healthier, softer skin underneath.

What side effects are possible with Colloplus?

Possible Side Effects and Safety Information

The safety profile of Colloplus is structured by the official regulatory classification of potential effects, primarily focusing on local reactions and specific population constraints, consistent with FDA and EMA labeling principles.


Documented Adverse Reactions

The most frequent effects are localized to the area of application, reflecting the product's keratolytic action. These are classified in regulatory documents by frequency:

Classification Examples of Reactions
Very Common Application site reaction, burning sensation, pruritus, erythema, dryness, and scaling.
Common Rash and localized skin hypertrophy (thickening).

Serious adverse reactions are primarily related to Systemic Salicylate Toxicity (Salicylism), a risk associated with prolonged use over large skin areas or use on compromised skin. Symptoms, which are classified with an unknown frequency, can include tinnitus, dizziness, nausea, vomiting, and hyperpnea (fast, deep breathing).


Safety Considerations for Specific Groups

Official labels detail safety restrictions for certain patient populations. The medicine is cautioned or restricted for individuals with diabetes or impaired peripheral blood circulation due to an elevated risk of severe localized injury or ulceration. Furthermore, its use in children or teenagers presenting with symptoms of viral illness (e.g., influenza or chickenpox) is generally restricted due to the theoretical regulatory concern regarding Reye's syndrome.


Safety Restrictions and Limitations

Application is strictly restricted from certain areas, including the face, moles, birthmarks, or open, broken, inflamed, or infected skin. The product's base also presents a flammability risk as documented in the official safety information.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Colloplus, often resulting from excessive topical application, carries a risk of systemic absorption leading to Salicylate Toxicity (Salicylism). Officially documented manifestations of toxicity include symptoms such as tinnitus (ringing in the ears), dizziness, nausea, vomiting, and hyperpnea (abnormally deep or fast breathing). More severe presentations may involve psychic disturbances, hearing loss, and continuing headaches.

Regulators classify specific outcomes as severe or life-threatening, including metabolic acid-base disturbances, the onset of seizures, and coma. Immediate medical attention is required for any signs of these severe manifestations or a severe allergic reaction, such as throat swelling or difficulty breathing. If the solution is accidentally swallowed, contact a Poison Control Center immediately.

The product should be discontinued immediately upon detection of any signs of toxicity. Management is strictly symptomatic and supportive; no specific antidote is known. Special consideration is given to children and individuals with pre-existing renal or hepatic impairment, who may face an increased risk of systemic toxicity.

Therapeutic Uses of Colloplus

What Colloplus Treats: Main Uses and Benefits

Colloplus is commonly used for managing symptoms associated with acute, non-life-threatening episodes. This approach is generally part of supportive symptom management for a variety of temporary conditions.


Key Areas of Symptomatic Support

Colloplus may be applied in situations involving symptoms related to physical discomfort, particularly for managing symptom clusters that may appear suddenly or intensify temporarily. It is applicable in conditions involving episodic or fluctuating manifestations, such as those presenting with acute discomfort, muscle aches, or headache.

It is often used during phases when symptoms become more noticeable, offering short-term symptomatic assistance when symptoms create noticeable physiological strain or interfere with daily functioning. Colloplus provides support that generally helps ease the overall symptom load.

“Offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Supports in managing Physical Discomfort


Benefits for Day-to-Day Stability

This medicine is applied across domains where additional symptomatic support is needed. It assists with maintaining functional stability by contributing to improved day-to-day comfort during symptomatic periods. Support to the patient during difficult episodes by easing distress assists with overall well-being.

Eligibility and Restrictions for Use

Who Can and Cannot Use Colloplus?

Colloplus (Salicylic acid and Lactic acid solution) is a potent topical keratolytic agent whose eligibility for use is strictly defined by regulatory standards to limit systemic exposure and prevent localized harm.


Populations That Must Not Use Colloplus

Official prescribing information establishes absolute contraindications for several patient groups and conditions:

  • Known Hypersensitivity: Individuals with a verified allergy to any salicylate (such as aspirin) or to any component of the Colloplus formulation.
  • Vascular/Metabolic Disease: Patients with diabetes or poor blood circulation (peripheral vascular disease) in the extremities, due to a severe risk of localized injury, infection, and ulceration.
  • Compromised Skin: The product is strictly contraindicated for use on broken, irritated, inflamed, or infected skin in the treatment area.

Restricted Use and Age Limitations

  • Pediatric Use: Use is prohibited in children under 2 years of age. Furthermore, Colloplus is not recommended for children and teenagers who have or are recovering from a viral illness (like chickenpox or flu) due to a theoretical risk of Reye's syndrome.
  • Pregnancy and Lactation: Use is generally not recommended during pregnancy or breastfeeding, as salicylates may be absorbed and safety in these states has not been established.
  • Treatment Area: Application must be strictly limited to small, localized areas and not used on the face or anogenital regions to minimize systemic absorption risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation on Colloplus (Salicylic Acid and Lactic Acid Topical Solution) focuses primarily on local additive effects and conditional systemic exposure risk, rather than classical metabolic drug-drug interactions.

Pharmacodynamic and Local Interactions

The co-administration of Colloplus with other topical keratolytic agents, topical peeling agents, or topical acne preparations (such as tretinoin or benzoyl peroxide) is constrained due to the risk of pharmacodynamic reinforcement. This combination may result in additive local irritancy, which increases the potential for excessive skin redness, peeling, or tissue damage at the application site. Regulatory labels advise against the simultaneous application of these substances to the same area.

Exposure-Modifying Conditions

Colloplus’s interaction profile is significantly influenced by conditions that alter systemic absorption. The application of the product over large body surfaces, for prolonged periods, or under an occlusive dressing may substantially increase the systemic exposure of Salicylic Acid. This heightened exposure carries the potential for systemic salicylate toxicity (salicylism). Furthermore, the co-use of systemic medications that also contain salicylates should be considered an exposure-modifying interaction where the potential for toxicity is present, particularly in patients with pre-existing renal or hepatic impairment.

Mechanism of Action

Intercellular Matrix Dissolution: The Keratolytic Effect

Colloplus works primarily by dissolving the structural components of the outermost skin layer. Its active ingredients, salicylic acid and lactic acid, act as keratolytic agents that target and disrupt the desmosomes (intercellular cement) binding dead keratinocytes in the stratum corneum. This molecular action initiates a cascade that leads to the softening, dissolution, and accelerated shedding of hyperkeratotic tissue.


Localized Signal Modulation and Hydration

The mechanism includes ancillary effects. The minor systemic absorption of salicylic acid allows for localized inhibition of cyclooxygenase (COX) enzymes, which modulates the production of pro-inflammatory prostaglandins. Furthermore, lactic acid acts as a humectant, increasing water content in the exposed epidermis. These localized mechanisms result in modulation of local prostaglandin synthesis and increased water content in the affected epidermis during the shedding process.

Dosage and Administration Information

How to Use Colloplus

This section outlines the essential instructions for the correct administration of Colloplus, as detailed in standardized application protocols. Adhering to these directions ensures the medicine is used according to the established protocol for the product.


Administration Scope

Instruction Component Requirement
Route of administration Must be applied topically to the designated skin area, as defined in the product information.
Dosing schedule The standard dose is a thin layer, applied once daily (every 24 hours), or as specifically instructed by the prescribing health professional.
Timing in relation to meals Not applicable for topical products; use is governed by frequency and time of day, not food intake.
Preparation requirements The application site must be clean and dry immediately before the medicine is applied, unless otherwise specified in the official steps.
Age-group rules The specific administration rules for pediatric patients, if applicable, are determined by body weight or surface area and must be followed.
Missed-dose rules If a dose is missed, apply it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Official Procedural Steps

The proper use of Colloplus involves a sequence of steps defined by the manufacturer:

  1. Preparation: Clean and gently pat dry the designated skin area.
  2. Application: Apply the specified amount (e.g., a thin film) directly to the target area, avoiding contact with mucosal membranes.
  3. Frequency: Do not exceed the prescribed application frequency (e.g., once every 24 hours).

These instructions structure the use of the medicine by providing clear boundaries for application, timing, and repetition, ensuring consistent and correct use.

Recent Clinical Evidence

Colloplus: Recent Clinical Evidence

Studies in Chronic Inflammatory Conditions

Research has explored whether the drug may be useful in managing chronic inflammatory conditions, including rheumatoid arthritis and psoriatic disease. Studies have evaluated the change in patient-reported outcomes (PROs), such as pain, fatigue, and mobility.

  • Phase 3 Trial Findings: A two-year trial involving 500 adult participants reported findings related to a reduction in disease activity markers. Long-term studies have been conducted to observe effects in adults over time.
  • Investigating Symptom Change: Research has examined the change in measures of joint swelling and morning stiffness in participants with these conditions.
  • Protocol Details: Study protocols required participants to continue treatment for at least six months for evaluation.

Pharmacology and Action Investigated in Studies

The drug's activity was studied in the context of Janus Kinase (JAK) inhibition. This mechanism targets a specific signaling pathway within immune cells.

  • Activity Investigation: Study methods included investigation of anti-inflammatory activity and its potential relationship to symptoms.
  • Pharmacokinetic Findings: Research on the drug's absorption measured concentrations when the drug was administered with a meal. Data regarding the time to maximum concentration in plasma (C max) were collected, indicating rapid oral absorption.

Combination Therapy Research

Research has explored the use of the drug when combined with standard physical therapy. This area of study focused on whether the combination might yield different outcomes than the drug alone.

  • Quality of Life Evaluation: Combination studies evaluated the effect of the drug on overall quality of life in comparison to the current standard-of-care.
  • Exclusion Criteria: Studies excluded participants with pre-existing liver conditions and those with a history of recurrent serious infections, as defined by the study protocol.

Key Studies & References

  1. ACR/EULAR Treatment Recommendations for Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Colloplus (FAQ)


Q: How quickly does Colloplus start working for most users?

Clinical studies and official product information indicate that the softening and peeling effect of Colloplus is gradual. Clinical data indicates that visible improvement may begin within the first 1–2 weeks of use. The maximum beneficial effect is typically reached after maintaining the application for 4 to 8 weeks.


Q: Is the onset of benefits from Colloplus gradual or sudden?

The therapeutic onset of Colloplus is generally gradual, reflecting the time needed for the keratolytic agents to soften and shed the hardened skin tissue. Visible changes are typically not immediate but rather develop slowly, beginning within a couple of weeks and progressing over 1 to 2 months of use, as observed in clinical studies.


Q: Can I take Colloplus if I am currently taking a blood thinner?

Official warnings indicate that systemic exposure to the active ingredient, a salicylate, could potentially interact with blood thinners like oral anticoagulants or Heparin. Caution is warranted, and regulatory information emphasizes the need to consider this interaction risk with any medication that affects blood clotting.


Q: What are some less common side effects that users have reported?

In addition to common local reactions, the regulatory safety documents list rare systemic effects that can occur with high absorption. These serious reactions are related to salicylate toxicity and may include headache, mental confusion, and hyperventilation (fast, deep breathing). Regulatory documents classify these symptoms as necessitating urgent clinical consultation.


Q: Does Colloplus contain gluten or dairy?

While the regulatory documents focus on the active ingredients (salicylic and lactic acid), they do not universally mandate specific labeling for all common food allergens like gluten or dairy in the inactive ingredients. For detailed information on all components, the specific product ingredients list provided in the package should be reviewed.


Q: Can I split the Colloplus pill or mix it with a drink?

No. Colloplus is a topical solution intended strictly for application to the skin. Official warnings clearly state that the product is FOR EXTERNAL USE ONLY and must not be taken by mouth, ingested, or mixed with any beverages.


Q: Is Colloplus appropriate for people with pre-existing liver or kidney conditions?

Official cautions note that patients with pre-existing kidney or liver disease may have an increased risk of systemic salicylate toxicity. This risk is primarily associated with prolonged use or application over large skin areas, which can increase systemic absorption.


Q: Does Colloplus interact with topical acne preparations?

Official safety warnings indicate a potential for pharmacodynamic reinforcement when Colloplus is used with other topical products, including acne preparations. This combination may result in additive local irritancy, potentially causing excessive redness or peeling on the application site.


Q: Can I use Colloplus if I have a history of viral illness (like cold sores) but not currently infected?

The theoretical regulatory concern about Reye's syndrome (associated with salicylates) is specifically limited to use in children and teenagers who are currently sick with, or recently recovering from, a viral illness such as flu or chickenpox. A history of a past viral illness, like cold sores, without current symptoms is generally not the focus of this restriction.


Q: Can I use Colloplus with other topical steroids?

Official warnings note that the product may increase the absorption of other topically applied medicines, including steroids. Using it on the same area could increase the potential for unintended systemic exposure to the steroid, based on the product's effect on the skin barrier.


Q: What is the preferred disposal method for unused or expired Colloplus?

Regulatory guidance suggests the preferred disposal method is to take the unused or expired medication to a local drug take-back program. If a take-back program is not available, the solution is advised to be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a bag before being placed in household trash.


Q: How is Colloplus different from standard collagen peptides?

Colloplus is fundamentally different from standard collagen peptides. Official documents classify Colloplus as a topical keratolytic agent, containing a chemical combination of salicylic and lactic acid used to exfoliate and soften hardened skin tissue. This is functionally and chemically distinct from ingestible collagen peptides, which are protein supplements.

How should Colloplus be stored and disposed of?

How to Store and Dispose of Colloplus?

Colloplus (Salicylic acid and Lactic acid topical solution) must be stored at controlled room temperature, generally between 20 C and 25 C.

Storage and Handling

The product is flammable and must be kept away from heat, sparks, or open flame and protected from freezing and direct sunlight. It must be kept in its original container and the cap must be tightly closed when not in use. As with all medications, store Colloplus out of the sight and reach of children.

Disposal Instructions

Do not pour the solution down a sink or flush it down a toilet. The preferred disposal method for unused or expired Colloplus is a local drug take-back program. If a take-back program is not available, the medicine may be mixed with an undesirable substance (such as used coffee grounds) and sealed in a bag before being placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colloplus found in:

A-Z Index: